Mallia Therapeutics Secures Funding For Hair Growth Drug CD83
The German biotech startup Mallia Therapeutics (formerly MalliaBiotech) has secured seed funding to further its hair loss drug soluble CD83.
CD83 Hair Growth Through Immune Modulation
On July 11, 2023, Mallia Therapeutics issued a press release announcing a successful seed financing round and the presentation of data at a European Hair Research Society (EHRS) meeting. The company, founded by researchers at the University Erlangen in Germany, first entered the news back in 2021 when their team was awarded the prestigious m4 award and grant to continue research on CD83 and hair loss. CD83 is a human protein which plays a role in immune functions. Prof. Alexander Steinkasserer, co-founder of Mallia Therapeutics, is a world leading expert in CD83 and has developed a soluble form of CD83 for therapeutic applications, sCD83.
sCD83 Mechanism of Hair Growth
For the first time, information has been shared publicly on sCD83’s mechanism of action in hair growth. In今天的发布,sCD83 was described to induce hair growth and the formation of new hair follicles in two ways: “Firstly, it induces an anti-inflammatory environment at the hair follicle via regulatory T cells (Tregs), which interact with follicular stem cells and thereby activate hair growth. Secondly, sCD83 directly binds to follicular stem cells where it induces the formation of new hair follicles.”
CSO of Mallia Therapeutics, Dr. Dmytro Royzman, presented preclinical data at the EHRS 2023 meeting showing sCD83 accelerated the anagen growing phase and induced new hair growth (likely in a mouse model, which is not significant), however, the company also presented human ex vivo data showing sCD83 was able to prolong the anagen phase in a human hair follicle and upregulate certain hair growth-promoting genes, which is more promising. Human ex vivo data involves culturing and testing human hair follicles which have been surgically extracted from a person’s scalp.
Co-founder of Mallia Therapeutics, Dr. Manfred Groeppel added in the news: “we hope to move into the clinic and start treating patients within the next two years.”This timeline is likely subject to Mallia raising funds in a successful Series A financing round.
Mallia Therapeutics New Website
In addition to the funding news, Mallia Therapeutics has finally rolled out its ownwebsite. The site contains all the usual sections; Leadership team, Science, News, etc., however it also has a section for Investors and Partnering. ThePartneringpage, in particular, shares an interesting detail. It states that Mallia is interested in partnering with cosmeceutical and pharmaceutical companies for the development of its hair loss programs. This appears to be an indication the sCD83 could be developed as a cosmeceutical in addition to a pharmaceutical drug, which we all know means a shorter pathway to market.